Clinical Trial Search

Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants

Primary: Time to Disease Progression — 15.2 weeks

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Overall Survival

Primary: Overall Response Rate — 6 percentage of patients

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks

Primary: Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer — 19 Participants

Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months

Primary: Partial Response in Bone Scan From Baseline to Week 6 — 9; 1; 6 participants

Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants

Primary: Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12 — 47; 89; 88; 22…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001

Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale

Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Efficacy: Best Objective Response Rate Percent by Treatment Group — 0; 0; 0; 0 Percent (%) of subjects

Primary: Median Time on Treatment — 11 weeks

Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants

Primary: Number of Patients With Gene Alterations — 7; 4; 7; 7 Participants

Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants

Primary: Radiographic Progression-Free Survival (rPFS) — 8.0; 3.7 months — p=<0.0001

Primary: Overall Response Rate (ORR) — 50 percentage of participants

Primary: Phase Ib Escalation Part: Number of Patients With Dose Limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213

Primary: Biochemical Response Rate — 0 participants

Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) — 9; 5; 4; 2 Participants

Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants

Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants